BDX — Becton, Dickinson and Company
$218.03
+$2.32 (+1.08%)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
Market Cap
$59.39B
Forward P/E
15.3x
52-Week Range
N/A
BDX Price History
Revenue vs. Net Income
$19.5B
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
$2.7B
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
5.3%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.8x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
3.5%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-0.9%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
